Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

April 2025

Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies

RMD Open. 2025;11:e005026. doi: 10.1136/rmdopen-2024-005026.

Ink B,

White K,

Mease et al. found that bimekizumab demonstrated a favourable long-term safety profile in patients with axSpA and PsA.

Keywords:

February 2025

Safety and efficacy of deucravacitinib in moderate to severe plaque psoriasis for up to 3 years: An open-label extension of randomized clinical trials

JAMA Dermatology 2025;161:56–66 doi: 10.1001/jamadermatol.2024.4688

Sofen H,

Papp KA,

Kisa RM,

Vaile J,

Hoyt K,

Armstrong et al. evaluated the long-term safety and efficacy of deucravacitinib in patients with moderate to severe plaque psoriasis over a three-year period. The study found that exposure-adjusted incidence rates of AEs remained stable or declined over time, with no new safety signals emerging. Clinical response rates, including PASI75/90, were maintained, supporting the drug’s long-term efficacy.